
VRTX
Healthcare · Biotechnology · $136.56B market cap
$538.60-4.02 (-0.7%)Nov 13, 4:06 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -16.6% over 90 days · 30-day revisions 1 up, 8 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 2, 2026 | After the close | 4.36 | 4.21 | -3.4% |
| Aug 3, 2026 | After the close | 4.15 | 4.20 | +1.2% |
| May 4, 2026 | After the close | 4.31 | 4.47 | +3.8% |
| Feb 12, 2026 | After the close | 5.15 | 5.03 | -2.3% |
| Nov 3, 2025 | After the close | 4.58 | 4.80 | +4.8% |
| Aug 4, 2025 | After the close | 4.25 | 4.52 | +6.4% |
| May 5, 2025 | After the close | 4.29 | 4.06 | -5.4% |
| Feb 10, 2025 | After the close | 4.02 | 3.98 | -1.0% |
| Nov 4, 2024 | After the close | 4.13 | 4.38 | +6.1% |
| Aug 1, 2024 | After the close | -11.75 | -12.83 | -9.2% |
| May 6, 2024 | After the close | 4.06 | 4.76 | +17.2% |
| Feb 5, 2024 | After the close | 4.09 | 4.20 | +2.7% |
| Nov 6, 2023 | After the close | 3.97 | 4.08 | +2.8% |
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one…
| Aug 1, 2023 | After the close | 3.88 | 3.89 | +0.3% |
| May 1, 2023 | After the close | 3.00 | 3.05 | +1.7% |
| Feb 7, 2023 | After the close | 3.51 | 3.76 | +7.1% |
| Oct 27, 2022 | After the close | 3.64 | 4.01 | +10.2% |
| Aug 4, 2022 | After the close | 3.50 | 3.60 | +2.9% |
| May 5, 2022 | After the close | 3.54 | 3.52 | -0.6% |
| Jan 26, 2022 | After the close | 3.29 | 3.37 | +2.4% |
| Nov 2, 2021 | After the close | 3.07 | 3.56 | +16.0% |
| Jul 29, 2021 | After the close | 2.38 | 3.11 | +30.7% |
| Apr 29, 2021 | After the close | 2.69 | 2.98 | +10.8% |
| Feb 1, 2021 | After the close | 2.55 | 2.51 | -1.6% |
| Oct 29, 2020 | After the close | 2.33 | 2.64 | +13.3% |
| Jul 30, 2020 | After the close | 2.08 | 2.61 | +25.5% |
| Apr 29, 2020 | After the close | 1.85 | 2.56 | +38.4% |
| Jan 30, 2020 | After the close | 1.22 | 1.70 | +39.3% |
| Oct 30, 2019 | After the close | 1.16 | 1.23 | +6.0% |
| Jul 31, 2019 | After the close | 1.07 | 1.26 | +17.8% |
| Apr 30, 2019 | After the close | 1.01 | 1.14 | +12.9% |
| Feb 5, 2019 | After the close | 1.06 | 1.30 | +22.6% |
| Oct 24, 2018 | After the close | 1.01 | 1.09 | +7.9% |
| Jul 25, 2018 | After the close | 0.75 | 0.94 | +25.3% |
| Apr 26, 2018 | After the close | 0.63 | 0.76 | +20.6% |
| Jan 31, 2018 | After the close | 0.54 | 0.61 | +13.0% |